New Dual-Action eye drug shows promise in early trial for Diabetes-Related vision loss
NCT ID NCT05940428
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested a new eye injection called ASKG712 in 10 people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The drug targets two proteins that cause leakage and abnormal blood vessel growth. The main goal was to check safety and how the body processes the drug, not yet to prove it works. Results will guide future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASKG712 (a protein injection that blocks two factors involved in abnormal blood vessel growth and leakage)
What this could lead to
If successful, this could lead to a new treatment option for diabetic macular edema that targets two pathways at once, potentially offering better or longer-lasting vision improvement.
What could go wrong
This is a very early (Phase 1) study with only 10 participants, so safety and dosing are the main focus—not yet proof of effectiveness. The treatment is injected directly into the eye, which carries risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, China